Mumbai, March 18 -- Under the terms of the strategic agreement, Shilpa Biologicals will support both development, including clinical studies, as well as long-term commercial supply through GMP manufacturing. Additionally, Shilpa Group will provide mAbTree access to India and several global markets via its extensive partner network.

Shilpa Biologicals will utilize its large R&D teams, providing full-service capabilities from cell line development to GMP drug product manufacturing, with manufacturing and clinical supply conducted at its state-of-the-art bio-manufacturing facility at Dharwad, Karnataka.

This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation an...